NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal TA440; Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine

Stakeholder list

Consultees

Company/sponsor

- Servier Laboratories Ltd (Irinotecan hydrochloride trihydrate)

Patient/carer groups

- Pancreatic Cancer Action

- Pancreatic Cancer UK

- South Asian Health Foundation

- Specialised Healthcare Alliance

Professional groups

- British Geriatrics Society

- Royal College of General Practitioners

- Royal College of Nursing

- Royal College of Pathologists

- Royal College of Physicians

- Royal Society of Medicine

- UK Clinical Pharmacy Association

Others

- Department of Health and Social Care

- NHS England

- NHS Harrow CCG

- NHS Redbridge CCG

- Welsh Government

Commentators

General commentators

- All Wales Therapeutics and Toxicology Centre

- Allied Health Professionals Federation

- Board of Community Health Councils in Wales

- British National Formulary

- Care Quality Commission

- Department of Health, Social Services and Public Safety for Northern Ireland

- Healthcare Improvement Scotland

- Medicines and Healthcare Products Regulatory Agency

- National Association of Primary Care

- National Pharmacy Association

- NHS Alliance

- NHS Confederation

- Scottish Medicines Consortium

- Welsh Health Specialised Services Committee

Comparators

- Roche (capecitabine)

Relevant research groups

- Genomics England

- MRC Clinical Trials Unit

- National Institute for Health Research

Associated Public Health groups

- Public Health England

- Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.